Pancreatic Cancer Research

ResearcherYanbian UniversityActive in the last 2 years

Yang Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1163-2359; OpenAlex author ID A5100397510. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 4 papers · 2024: none · 2025: 2 papers

Papers 9

  1. Association of LAMA3 expression with perineural invasion and chemoresistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12672-025-03971-5↗
  2. Feasibility analysis and development trend of nanomaterials for the treatment of pancreatic cancer. Co-author DOI 10.1186/s11671-025-04259-x↗
  3. NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer. Co-author DOI 10.1002/cam4.5774↗
  4. Identification of novel potential homologous repair deficiency-associated genes in pancreatic adenocarcinoma via WGCNA coexpression network analysis and machin… Co-author DOI 10.1080/15384101.2023.2293594↗
  5. NQO1/CPT1A promotes the progression of pancreatic adenocarcinoma via fatty acid oxidation. Co-author DOI 10.3724/abbs.2023066↗
  6. PITX2 in pancreatic stellate cells promotes EMT in pancreatic cancer cells via the Wnt/β-catenin pathway. Co-author DOI 10.3724/abbs.2023118↗
  7. Hsa_circ_0074298 promotes pancreatic cancer progression and resistance to gemcitabine by sponging miR-519 to target SMOC. Co-author DOI 10.7150/jca.62927↗
  8. Elevated expression of Tiam1 is associated with poor prognosis and promotes tumor progression in pancreatic cancer. Co-author DOI 10.2147/ott.s171425↗
  9. Clinicopathological implications of NQO1 overexpression in the prognosis of pancreatic adenocarcinoma. Co-author DOI 10.3892/ol.2017.5821↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yeben Qian · 1 shared paper, 2025 · strength 0.33
  2. Jingyao Zhu · 1 shared paper, 2025 · strength 0.28
  3. HongJian Guan · 1 shared paper, 2025 · strength 0.28
  4. Yang Dawei · 1 shared paper, 2023 · strength 0.19
  5. Huan Ouyang · 1 shared paper, 2023 · strength 0.19
  6. Ran Xu · 1 shared paper, 2023 · strength 0.19
  7. Hao Chen · 1 shared paper, 2023 · strength 0.19
  8. Chun Liu · 1 shared paper, 2023 · strength 0.19
  9. Congya Zhou · 1 shared paper, 2023 · strength 0.18
  10. Di Wu · 1 shared paper, 2023 · strength 0.18
  11. Xiaowu Xu · 1 shared paper, 2023 · strength 0.18
  12. Qunli Xiong · 1 shared paper, 2023 · strength 0.18
  13. Xuemin Chen · 1 shared paper, 2023 · strength 0.18
  14. Yongfeng Xu · 1 shared paper, 2023 · strength 0.18
  15. Yue Zhang · 1 shared paper, 2023 · strength 0.18
  16. Zhu Zeng · 1 shared paper, 2023 · strength 0.18
  17. Qing Zhu · 1 shared paper, 2023 · strength 0.18
  18. Yi Qin · 1 shared paper, 2023 · strength 0.18
  19. Liyan Chen · 2 shared papers, 2017–2018 · strength 0.17
  20. Zhenhua Lin · 2 shared papers, 2017–2018 · strength 0.17
  21. Zeqian Yu · 1 shared paper, 2022 · strength 0.16
  22. Jiahua Zhou · 1 shared paper, 2022 · strength 0.16
  23. Chen Hong · 1 shared paper, 2022 · strength 0.16
  24. Mina Ding · 1 shared paper, 2018 · strength 0.09
  25. Meiying Ji · 1 shared paper, 2017 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.